Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

Østergaard, Lars; Lebacq, E.; Poolman, Jan; Maechler, Gudrun; Boutriau, Dominique

doi:10.1016/j.vaccine.2008.08.075

Cited by 86 publications

(71 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, when the GlaxoSmithKline rSBA assays were used, all subjects had rSBA titers of Ն1:8 and at least 99.5% had rSBA titers of Ն1:128, with large fold increases in rSBA GMTs. These observations are consistent with the results of previous studies evaluating the immune responses to MenACWY-TT in adolescents and young adults (34,35).…”

Section: Discussionsupporting

confidence: 93%

“…Pain at the injection site tended to be reported more frequently for participants who received the MenACWY-TT vaccine than the Men-PS vaccine. This observation is consistent with previous studies showing that injection site reactions are more frequent in individuals vaccinated with MenACWY-TT versus Men-PS (35,36,45,46) and those vaccinated with other quadrivalent meningococcal conjugate vaccines versus plain PS vaccines (47,48). It is likely that the increased reactogenicity following vaccination with the MenACWY-TT vaccine is due to the TT component (49).…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Meningococcal Polysaccharide A O -Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years

Lupisan

Limkittikul

Sosa³

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

(ACWY-B) (92% O-acetylation), or Men-PS (82% O-acetylation).Immunogenicity was evaluated in terms of serum bactericidal activity using rabbit complement (i.e., rabbit serum bactericidal activity [rSBA]). Solicited symptoms, unsolicited adverse events (AEs), and serious AEs (SAEs) were recorded. The immunogenicities, in terms of rSBA geometric mean titers, were comparable for both lots of MenACWY-TT. The vaccine response rates across the serogroups were 79.1 to 97.0% in the two ACWY groups and 73.7 to 94.1% in the Men-PS group. All subjects achieved rSBA titers of >1:8 for all serogroups. All subjects in the two ACWY groups and 99.5 to 100% in the Men-PS group achieved rSBA titers of >1:128. Pain was the most common solicited local symptom and was reported more frequently in the ACWY group (53.9 to 54.7%) than in the Men-PS group (36.8%). The most common solicited general symptoms were fatigue and headache, which were reported by 28.6 to 30.3% and 26.9 to 31.0% of subjects, respectively. Two subjects reported SAEs; one SAE was considered to be related to vaccination (blighted ovum; ACWY-B group). The level of serogroup A PS O-acetylation did not affect vaccine immunogenicity. Men-ACWY-TT (lot A) was not inferior to Men-PS in terms of vaccine response and was well tolerated.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 92%

Meningococcal Polysaccharide A O -Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years

Lupisan

Limkittikul

Sosa³

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Similar results have also been demonstrated in studies conducted in Asia and continental Europe which compared a quadrivalent tetanus toxoid conjugate meningococcal vaccine and MenACWY-PS (16)(17)(18). The differences seen in the current study may relate to geographical variations in meningococcal nasopharyngeal carriage between the United Kingdom study population and those from previous studies leading to differential degrees of natural priming or may be due to differences in the comparator polysaccharide vaccine used.…”

Section: Discussionsupporting

confidence: 85%

Randomized Clinical Trial To Evaluate the Immunogenicity of Quadrivalent Meningococcal Conjugate and Polysaccharide Vaccines in Adults in the United Kingdom

Ramasamy

Clutterbuck

Haworth

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

“…MenACWY-TT aşısının çocuk, adolesan, erişkin ve 55-103 yaş arası popülasyonda da immünojenik ve güvenilir olduğu yapılan çalışmalarda gösterilmiştir (25)(26)(27)(28)(29)(30)(31)(32)(33)(34) . Baxter ve ark.…”

Section: Menacwy-tt Ile Ilgili Yürütülen Antikor Sürekliliğiunclassified

Meningococcal Vaccines

Somer¹,

Acar²

2017

Cocuk Dergisi

View full text Add to dashboard Cite

show abstract

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

Cited by 86 publications

References 24 publications

Meningococcal Polysaccharide A O -Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years

Meningococcal Polysaccharide A O -Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years

Randomized Clinical Trial To Evaluate the Immunogenicity of Quadrivalent Meningococcal Conjugate and Polysaccharide Vaccines in Adults in the United Kingdom

Meningococcal Vaccines

Contact Info

Product

Resources

About